Viking Therapeutics, Inc. (VKTX), a clinical-stage biopharmaceutical company, is making significant strides in its pipeline of treatments for obesity, liver diseases, and rare disorders. Recent updates highlight the progress and potential of their key therapeutic candidates.
VK2735 to Advance to Phase 3 for Obesity
One of the most notable developments is the advancement of VK2735, an oral medication for obesity. With positive results from Phase 2 studies, Viking Therapeutics is preparing for an End-of-Phase 2 meeting planned for the second half of 2024. This crucial meeting will lay the groundwork for the anticipated launch of Phase 3 trials, marking a significant step forward in addressing the global obesity epidemic.
VK2735 Phase 2 Study Expected to Begin in 4Q24
Building on the success of VK2735, Viking Therapeutics is gearing up to initiate a Phase 2 study in obesity by the fourth quarter of 2024. This study aims to further evaluate the efficacy and safety of VK2735, providing more comprehensive data to support its therapeutic potential.
Positive Results from VK2809 in NASH/MASH
In June, Viking Therapeutics reported positive biopsy results from their VK2809 program, which targets nonalcoholic steatohepatitis (NASH) and metabolic-associated steatohepatitis (MASH). The encouraging data has paved the way for an End-of-Phase 2 meeting scheduled for the fourth quarter of 2024. This meeting will be critical in determining the future direction of VK2809 and its potential to address these challenging liver diseases.
VK0214 Phase 1b Study in X-ALD
Viking Therapeutics has also completed enrollment in a Phase 1b study of VK0214 for X-linked adrenoleukodystrophy (X-ALD), a rare and debilitating genetic disorder. The data from this study is expected in the second half of 2024. This milestone represents a significant step in developing effective treatments for patients suffering from this rare condition.
Novel Amylin Agonist Program
At the American Diabetes Association (ADA) meeting in June, Viking Therapeutics presented in vivo data from their novel amylin agonist program. This program aims to develop new treatments for obesity, with an Investigational New Drug (IND) application planned for 2025. The promising preclinical results underscore the potential of this innovative approach in tackling obesity.
Financial Performance
As of the close of trading, Viking Therapeutics’ stock stood at $50.41, reflecting a decrease of 2.19%. However, after hours trading showed a significant increase to $60.90, up by 20.81%. This volatility highlights the market’s keen interest in Viking Therapeutics’ developments and the potential impact of their pipeline progress.
Whats next ?
Viking Therapeutics is poised for a transformative year with multiple key milestones on the horizon. From advancing VK2735 for obesity to progressing VK2809 in NASH/MASH and exploring novel treatments for X-ALD and obesity, the company’s robust pipeline reflects its commitment to addressing significant unmet medical needs. Investors and stakeholders will be closely watching as Viking Therapeutics continues to make strides in its mission to improve patient outcomes in these critical areas.
